Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OK99 Stem Cell Transplantation in Severe Parkinson's Disease
NCT02780895Phase 1Unknown
- Sponsor
- Celavie Biosciences LLC
- Start
- May 2014
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OK99 in Parkinson's disease (PD), sponsored by Celavie Biosciences LLC. Primary endpoint: Safety as Measured by the Number and Severity of Adverse Events at 3 years. Status: unknown.
02
Drugs
OK99
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02780895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780895.